Delivery Order SPE2DB22D3501-SPE2DB25FXH70
- Not listed
- The Defense Logistics Agency awarded a $36,747.91 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampuls (2.5 ml units) with an ultimate completion date of October 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,356.71 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampule 2.5ml pharmaceutical supplies. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 18, 2025, issued on September 17, 2025. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL pharmaceutical product, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $24,134.90 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml units) with a firm fixed price structure. This is a non-set-aside competitive award with a completion date of December 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml units) with a ceiling value of $12,701.74. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 27, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under the company's larger...
- The Defense Logistics Agency awarded a $49,798.78 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampul 2.5ml pharmaceutical products. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of July 21, 2025. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a $2,599.62 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml) on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml pharmaceutical product, with a ceiling value of $8,168.13 under a firm fixed-price contract type. This delivery order represents a non-set-aside award issued to the vendor's Conshohocken, Pennsylvania location and is scheduled for ultimate completion by October 22, 2025. The contract is a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $11,346.15 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Pulmozyme 1 mg/ml ampuls in 2.5 ml units. The contract, with an ultimate completion date of September 15, 2025, carries no set-aside designation and represents a competitive award under AmerisourceBergen's existing federal pharmaceutical supply agreements. Performance will be executed from the contractor's Corporate Office location in...
- The Defense Logistics Agency awarded a $4,516.47 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml). This is a non-set-aside contract with an ultimate completion date of September 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXH70Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml units) under a firm fixed-price contract with a ceiling value of $10,076.66. The order was competitively awarded without set-aside designation and is scheduled for completion by September 16, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. As a prime vendor under the DLA Medical Supply Chain, the company supplies a comprehensive range of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Pulmozyme is a specialty medication used in respiratory care, consistent with AmerisourceBergen's extensive portfolio of brand-name and generic drugs, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's competitive selection for this and numerous other federal contracts demonstrates its capability to meet stringent procurement requirements in the federal medical supply sector.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 9/15/25 |